Equity Overview
Price & Market Data
Price: $25.50
Daily Change: +$0.75 / 2.94%
Daily Range: $24.40 - $26.23
Market Cap: $1,537,731,968
Daily Volume: 244,610
Performance Metrics
1 Week: -3.52%
1 Month: -0.51%
3 Months: 2.16%
6 Months: 207.6%
1 Year: 779.3%
YTD: 10.82%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.